Zuneca Pharmaceutical vs. Natrapharm, Inc.

Under the Intellectual Property Code of the Philippines (R.A. No. 8293), ownership of a trademark is acquired through registration made validly in accordance with law, abandoning the previous rule that ownership is acquired through actual use; however, Section 159.1 protects a prior user in good faith by exempting such user from infringement liability, permitting the concurrent use of confusingly similar marks by the registrant and the prior user, provided the prior user's right to the mark may only be transferred or assigned together with the enterprise or business in which the mark is used.

Petitioner Zuneca Pharmaceutical has been engaged in the importation and sale of generic medicines in the Philippines since 1999. In 2003, it secured a Certificate of Product Registration from the Bureau of Food and Drugs (BFAD) for carbamazepine, an anti-convulsant drug, under the brand name "ZYNAPS," and commenced marketing the product in 2004. Respondent Natrapharm, Inc. is a domestic corporation manufacturing pharmaceutical products, including citicoline (for cerebrovascular disease/stroke) under the trademark "ZYNAPSE," which it registered with the Intellectual Property Office (IPO) on September 24, 2007. Both marks were admitted by the parties to be confusingly similar. Natrapharm filed a complaint for trademark infringement against Zuneca in November 2007, seeking damages and injunctive relief. Zuneca counterclaimed, asserting prior use and alleging that Natrapharm fraudulently registered "ZYNAPSE" despite knowledge of Zuneca's existing "ZYNAPS" mark.

The Competing Marks and Products: - Zuneca: Petitioner Zuneca Pharmaceutical, operated by Dr. Venus S. Arain and later incorporated as Zuneca, Inc. with Akram Arain as President, imported generic drugs from Pakistan. It obtained a Certificate of Product Registration for "ZYNAPS" (carbamazepine) on April 15, 2003, and commenced marketing in 2004. "ZYNAPS" is an anti-convulsant used for seizure disorders. - Natrapharm: Respondent Natrapharm, Inc. manufactured "ZYNAPSE" (citicoline), a drug for cerebrovascular disease/stroke. It registered the "ZYNAPSE" trademark with the IPO on September 24, 2007 (Certificate No. 4-2007-005596).

The Dispute: Natrapharm filed its complaint in November 2007, alleging that Zuneca's "ZYNAPS" was confusingly similar to its registered "ZYNAPSE," creating a likelihood of confusion dangerous to public health given the different medical indications. Natrapharm sought damages, injunction, and destruction of infringing materials. Zuneca counterclaimed, asserting that as the prior user of "ZYNAPS" since 2004, it had ownership rights superior to Natrapharm's registration, and alleged that Natrapharm acted in bad faith by registering "ZYNAPSE" despite knowledge of "ZYNAPS" through industry publications (Philippine Pharmaceutical Directory) and medical conventions where both companies exhibited.

Lower Courts' Findings: The RTC found that Natrapharm was a first registrant in good faith, having conducted searches in the IPO, BFAD, and IMS-PPI databases, and found no confusingly similar marks. The RTC applied the "first-to-file" rule, holding that registration defeats prior use where the prior user failed to register. The CA affirmed, ruling that under the IP Code, ownership is acquired through registration, not use, and that Zuneca failed to prove Natrapharm's bad faith by clear evidence.

• Prior Use as Basis of Ownership: Zuneca maintained that under Berris Agricultural Co., Inc. v. Abyadang and E.Y. Industrial Sales, Inc. v. Shen Dar Electricity and Machinery Co., Ltd., ownership of a trademark is acquired by registration and actual use, and that as between actual use without registration and registration without actual use, the former prevails. As the prior user of "ZYNAPS" since 2004, Zuneca argued its rights should prevail over Natrapharm's 2007 registration.
• Bad Faith Registration: Zuneca alleged that Natrapharm registered "ZYNAPSE" in bad faith, arguing that Natrapharm's presence in the same industry publications (PPD) and attendance at the same medical conventions as Zuneca created constructive knowledge of the "ZYNAPS" mark, rendering Natrapharm's registration fraudulent and void.
• Laches and Abandonment: Zuneca argued that Natrapharm's failure to oppose Zuneca's use and its delay in filing suit constituted laches and that Zuneca had not abandoned its mark.

• Registration as Sole Mode of Acquisition: Natrapharm countered that Section 122 of the IP Code explicitly provides that rights in a mark are acquired through registration, abandoning the prior use doctrine of the old Trademark Law. It argued that the first-to-file rule under Section 123.1(d) prioritizes the first filer, and that the prior user has no right to cancel a registration based solely on prior use.
• Good Faith Registration: Natrapharm argued that its registration was made in good faith after conducting due diligence searches in the IPO, BFAD, and industry databases (IMS-PPI), which revealed no confusingly similar marks. It denied knowledge of "ZYNAPS" prior to registration, noting that "ZYNAPSE" was coined from the neurological term "synapse."
• Infringement Liability: Natrapharm contended that Zuneca was liable for infringement for using a mark confusingly similar to its registered "ZYNAPSE," and that Section 159.1 only exempts prior use before the filing date, not continued use thereafter.

• Acquisition of Ownership: Whether ownership of a trademark under the IP Code is acquired through registration or prior use, and whether the first-to-file registrant defeats the rights of a prior user in good faith.
• Bad Faith: Whether Natrapharm registered the "ZYNAPSE" mark in bad faith.
• Infringement and Remedies: Whether Zuneca is liable for trademark infringement and subject to damages, injunction, and destruction of goods.
• Prior User Defense: Whether Section 159.1 of the IP Code protects a prior user in good faith from infringement liability and permits concurrent use of the mark.

• Acquisition of Ownership Through Registration: Ownership of a mark is acquired through registration under Section 122 of the IP Code. The law abandoned the "first-to-use" regime of the Trademark Law (R.A. No. 166), as evidenced by the removal of the phrase "previously used in the Philippines by another and not abandoned" from Section 123.1(d) and the legislative intent expressed in the sponsorship speech of Senator Raul Roco to comply with the TRIPS Agreement. The prima facie presumption of ownership from a certificate of registration (Section 138) is rebuttable only on grounds such as bad faith, non-use, abandonment, or genericide, not by mere prior use.
• Rectification of Prior Jurisprudence: The statements in Berris that "ownership of a trademark is acquired by its registration and its actual use" and in E.Y. Industrial Sales that "proof of prior and continuous use is necessary to establish ownership" were clarified as inconsistent with the IP Code's registration-based system. Berris was decided correctly based on the first-to-file result, but its reasoning regarding prior use as a mode of acquisition was erroneous under the IP Code. E.Y. Industrial Sales applied the old Trademark Law and is inapplicable to marks registered or first used after the IP Code's effectivity in 1998.
• Bad Faith Not Established: Good faith is presumed in trademark registration. Bad faith—defined as knowledge of prior creation, use, or registration by another—must be proven by clear evidence. Zuneca failed to discharge this burden. Natrapharm's evidence showed it conducted database searches and coined the mark independently. Mere possibility of knowledge through industry publications or conventions is insufficient to prove bad faith.
• Prior User Protection Under Section 159.1: Section 159.1 exempts from infringement liability any person who, in good faith, was using the mark for the purposes of his business before the filing or priority date of the registered mark. This protection extends to continued use after registration, not merely use prior to the filing date. The proviso that the right may only be transferred "together with his enterprise or business" confirms that the law contemplates concurrent use by the registrant and the prior user, but limits the alienability of the prior user's right to prevent uncontrolled expansion of the exception.
• Remedies Set Aside: Because Zuneca is a prior user in good faith protected by Section 159.1, it is not liable for trademark infringement. Consequently, the awards of damages (actual, exemplary, attorney's fees), the injunction against use, and the order for destruction of goods were set aside as having no basis under Sections 156 and 157, which require a finding of infringement.
• Public Health Safeguards: To mitigate the risk of medical switching between "ZYNAPS" (carbamazepine) and "ZYNAPSE" (citicoline), the Court ordered both parties to indicate on packaging, in plain language, the medical conditions treated and warnings regarding improper use, and directed the FDA to monitor compliance.

• First-to-File Rule and Registration as Mode of Acquisition — Under the IP Code (R.A. No. 8293), particularly Sections 122 and 123.1(d), ownership of a trademark is acquired exclusively through valid registration with the IPO. The first person to file an application for registration generally acquires ownership, provided the registration is not obtained fraudulently or contrary to law. This regime replaced the "first-to-use" rule under the old Trademark Law (R.A. No. 166), where prior use and non-abandonment determined ownership. The Court applied this to hold that Natrapharm, as the first registrant in good faith, is the lawful owner of the "ZYNAPSE" mark.
• Prior User in Good Faith Defense (Section 159.1) — Section 159.1 of the IP Code provides a limitation to infringement actions, protecting a person who, in good faith, was using an identical or similar mark for business purposes before the filing or priority date of the registrant's application. This protection allows the prior user to continue using the mark even after the registrant's mark is registered, effectively permitting concurrent use. However, the prior user's right is restricted: it may only be transferred or assigned together with the enterprise or business or that part of the enterprise in which the mark is used, preventing the uncontrolled proliferation of the mark by third parties unrelated to the original prior user's business.
• Bad Faith in Trademark Registration — Registration obtained with knowledge of a prior identical or similar mark created, used, or registered by another constitutes bad faith or fraud, rendering the registration void under Section 151.1(b) of the IP Code. Bad faith presupposes deliberate intent to cause damage or prejudice by appropriating another's goodwill. Good faith is presumed, and the burden of proving bad faith rests on the party alleging it. The Court found that mere attendance at the same conventions or listing in the same industry directories does not constitute sufficient proof of knowledge of the prior mark.

• "Under the IP Code, the ownership of a trademark is acquired by its registration." — Rectification of the statement in Berris that ownership is acquired by registration and actual use, clarifying that actual use is required only to maintain registration (via Declaration of Actual Use), not to acquire ownership.
• "Section 159.1 of the IP Code clearly contemplates that a prior user in good faith may continue to use its mark even after the registration of the mark by the first-to-file registrant in good faith, subject to the condition that any transfer or assignment of the mark by the prior user in good faith should be made together with the enterprise or business or with that part of his enterprise or business in which the mark is used." — Interpretation of the prior user defense allowing concurrent use.
• "Bad faith means that the applicant or registrant has knowledge of prior creation, use and/or registration by another of an identical or similar trademark. In other words, it is copying and using somebody else's trademark." — Definition of bad faith in registration, citing Mustang-Bekleidungswerke GmbH + Co. KG v. Hung Chiu Ming.
• "The removal of such a right [to cancel based on prior use] unequivocally shows the intent of the lawmakers to abandon the regime of ownership under the Trademark Law, as amended." — On the legislative intent behind Section 123.1(d) of the IP Code removing the "previously used... and not abandoned" language.

• Berris Agricultural Co., Inc. v. Abyadang, 647 Phil. 517 (2010) — Distinguished and clarified. While the result (first registrant wins) was correct, the Court rectified the dictum that ownership is acquired by registration and actual use, holding that under the IP Code, registration alone confers ownership.
• E.Y. Industrial Sales, Inc. v. Shen Dar Electricity and Machinery Co., Ltd., 648 Phil. 572 (2010) — Distinguished as applying the old Trademark Law (R.A. No. 166) where prior use was required for registration, and thus inapplicable to marks registered or first used after the IP Code's effectivity in 1998.
• Shangri-la International Hotel Management, Ltd. v. Developers Group of Companies, Inc., 520 Phil. 935 (2006) — Cited for the definition of bad faith as knowledge of prior use, but distinguished as having been decided under the old Trademark Law regime.
• Prosource International, Inc. v. Horphag Research Management SA, 620 Phil. 539 (2009) — Followed for the elements of trademark infringement under the IP Code.

• Section 122, Republic Act No. 8293 (Intellectual Property Code) — "How Marks are Acquired. - The rights in a mark shall be acquired through registration made validly in accordance with the provisions of this law." Applied as the statutory basis for the first-to-file rule.
• Section 123.1(d), Republic Act No. 8293 — "Registrability... A mark cannot be registered if it: (d) Is identical with a registered mark belonging to a different proprietor or a mark with an earlier filing or priority date..." Applied to establish the priority of the first filer.
• Section 138, Republic Act No. 8293 — "Certificates of Registration. - A certificate of registration of a mark shall be prima facie evidence of the validity of the registration, the registrant's ownership of the mark..." Applied to establish the presumption of ownership arising from registration.
• Section 147.1, Republic Act No. 8293 — "Rights Conferred. - The owner of a registered mark shall have the exclusive right to prevent all third parties not having the owner's consent from using in the course of trade identical or similar signs..." Applied as the general rule of exclusivity, subject to Section 159.1.
• Section 151.1(b), Republic Act No. 8293 — "Cancellation... A petition to cancel... may be filed... at any time, if... its registration was obtained fraudulently or contrary to the provisions of this Act..." Applied to discuss voidness of registrations obtained in bad faith.
• Section 155, Republic Act No. 8293 — "Remedies; Infringement." Applied to define the acts constituting infringement.
• Section 156, Republic Act No. 8293 — "Actions, and Damages and Injunction for Infringement." Applied to establish that remedies for infringement are available only to the owner of a registered mark against an infringer.
• Section 157, Republic Act No. 8293 — "Power of Court to Order Infringing Material Destroyed." Applied to establish that destruction of goods is a remedy contingent upon a finding of infringement.
• Section 159.1, Republic Act No. 8293 — "Limitations to Actions for Infringement... a registered mark shall have no effect against any person who, in good faith, before the filing date or the priority date, was using the mark for the purposes of his business or enterprise: Provided, That his right may only be transferred or assigned together with his enterprise or business..." Applied as the basis for exempting Zuneca from liability and allowing continued concurrent use.
• Section 6(b), Republic Act No. 6675 (Generics Act of 1988), as amended by Republic Act No. 9502 — Mandates that medical practitioners write prescriptions using generic names, with brand names optional. Cited to mitigate concerns about medical switching.

• Justice Perlas-Bernabe — Filed a Concurring Opinion.
• Justice Gesmundo — Filed a Separate Concurring Opinion, emphasizing the public health implications of confusingly similar drug names and urging legislative action.
• Chief Justice Peralta, and Justices Reyes, Jr., Hernando, Carandang, Lazaro-Javier, Inting, Zalameda, Lopez, Delos Santos, Gaerlan, and Baltazar-Padilla — Concurred in the majority decision.

• Justice Leonen — Dissented, expressing doubts regarding the abandonment of the ownership-through-use regime, arguing that legislative deliberations are insufficient to override the text of the law and that the continued requirement of actual use (via Declaration of Actual Use) suggests that use remains relevant to ownership.
• Justice Perlas-Bernabe and Justice Lazaro-Javier — Filed a joint Dissenting Opinion (noted in the header as "Dissenting Opinion, Perlas-BernabeLAzaro-Javier"), likely sharing similar reservations regarding the interpretation of Section 159.1 and the coexistence of confusingly similar marks in the pharmaceutical context.